MARKET

ZNTL

ZNTL

ZENTALIS PHARMACEUTICALS, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

47.02
-0.78
-1.63%
Opening 11:21 07/02 EDT
OPEN
48.51
PREV CLOSE
47.80
HIGH
48.98
LOW
46.00
VOLUME
24.42K
TURNOVER
--
52 WEEK HIGH
59.32
52 WEEK LOW
22.00
MARKET CAP
1.69B
P/E (TTM)
-35.5270
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ZNTL stock price target is 44.75 with a high estimate of 45.00 and a low estimate of 44.00.

EPS

ZNTL News

More
Zentalis Pharmaceuticals Announces the Appointment of Dr. Kimberly Blackwell to its Board of Directors
Zentalis Pharmaceuticals, Inc. (ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Kimberly Blackwell, M.D
GlobeNewswire · 1d ago
The Daily Biotech Pulse: Chiasma, Heron Await FDA Decisions, DBV Restructures, 3 Biopharmas Make Wall Street Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 25)
Benzinga · 6d ago
The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 17)
Benzinga · 06/18 12:34
Zentalis Pharmaceuticals To Present Preclinical Data On ZN-c5 At Upcoming AACR Virtual Annual Meeting II Jun. 22
NEW YORK and SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics
Benzinga · 06/15 20:32
Zentalis Pharmaceuticals to Present Preclinical Data on ZN-c5 at the Upcoming AACR Virtual Annual Meeting II
NEW YORK and SAN DIEGO, June 15, 2020 -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small.
GlobeNewswire · 06/15 20:30
Is It Too Late to Jump In on Zentalis?
The company's share price has nearly tripled since its IPO less than two months ago. Is it too late to get in on the fun?
Motley Fool · 06/03 11:07
72 Biggest Movers From Friday
Gainers Adaptimmune Therapeutics plc (NASDAQ: ADAP) shares jumped 127.8% to close at $11.07 on Friday after the company announced updated data from its ADP-A2M4 Phase 1 trial at the American Society for Clinical Oncology Annual Meeting.
Benzinga · 06/01 08:53
Zentalis Pharmaceuticals to Participate in Jefferies Virtual Healthcare Conference
GlobeNewswire · 05/28 21:05

Industry

Pharmaceuticals
+0.52%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About ZNTL

Zentalis Pharmaceuticals, Inc., formerly Zentalis Pharmaceuticals LLC., is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics targeting fundamental biological pathways of cancers. It is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative. Its other products include ZN-c3, an oral and small molecule inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of cell lung cancer.
More

Webull offers kinds of Zentalis Pharmaceuticals Inc stock information, including NASDAQ:ZNTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZNTL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZNTL stock methods without spending real money on the virtual paper trading platform.